Louann Albano
Family Health · Lakeland, FLNPI 1841597549
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 45 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 23.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $292 and has fallen 85.1% since, to $44 in 2024.
Across 45 payments — averaging $17.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$188
- Pfizer$111
- AstraZeneca$96
- Novo Nordisk$65
- Lilly USA, LLC$61
- Bayer$49
- plus $231 from 9 others
What the payments were for
- Food & beverage$801100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 10 | $188 |
| Pfizer | 6 | $111 |
| AstraZeneca | 7 | $96 |
| Novo Nordisk | 4 | $65 |
| Lilly USA, LLC | 4 | $61 |
| Bayer | 2 | $49 |
| Dexcom, Inc. | 2 | $42 |
| GSK | 2 | $37 |
| Abbott | 2 | $31 |
| Sanofi-aventis U.S. LLC | 1 | $29 |
| Boehringer Ingelheim | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Novartis | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
How this compares
$801 in reported general payments places this provider in the 60th percentile of 25 family health providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 74 | $73,601 |
| JardianceEmpagliflozin | 42 | $44,781 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 42 | $37,804 |
| FarxigaDapagliflozin Propanediol | 25 | $33,650 |
| JanuviaSitagliptin Phosphate | 21 | $32,753 |
| MounjaroTirzepatide | 17 | $18,499 |
| JanumetSitagliptin Phos/Metformin Hcl | 13 | $15,411 |
| MyrbetriqMirabegron | 17 | $12,892 |
| SymbicortBudesonide/Formoterol Fumarate | 40 | $11,759 |
| Incruse ElliptaUmeclidinium Bromide | 16 | $10,678 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $9,576 |
| BrilintaTicagrelor | 13 | $9,203 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 39 | $6,378 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 197 | $5,351 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $4,031 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $111 | $73,60174 claims |
| AstraZenecaFarxiga, Symbicort, Brilinta | $96 | $54,61278 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $37 | $48,48258 claims |
| Boehringer IngelheimJardiance | $21 | $44,78142 claims |
| Lilly USA, LLCMounjaro | $61 | $18,49917 claims |
| AbbVieSynthroid | $188 | $1,04212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 25 family health providers in Florida.
Other family health in Lakeland
- Teresa Gongora-GarciaMiami$14K
- Cindy BrownNaples$3K
- Cristina RickettiTampa$2K
- Janet ChinOakland Park$1K
- Raul LozanoHollywood$1K
- Erica FosslerMarathon$929
- Hae Jin HongTampa$912
- Beatrix PerniaApopka$883
- Deborah McCormickNaples$803
- Vivian SalinasMiami$609
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.